Abstract
Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-36 |
| Number of pages | 14 |
| Journal | Heart Failure Clinics |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2008 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Ventricular-Vascular Interaction in Heart Failure. / Borlaug, Barry A; Kass, David A.
In: Heart Failure Clinics, Vol. 4, No. 1, 01.2008, p. 23-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ventricular-Vascular Interaction in Heart Failure
AU - Borlaug, Barry A
AU - Kass, David A.
PY - 2008/1
Y1 - 2008/1
N2 - Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.
AB - Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.
UR - http://www.scopus.com/inward/record.url?scp=39649106311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39649106311&partnerID=8YFLogxK
U2 - 10.1016/j.hfc.2007.10.001
DO - 10.1016/j.hfc.2007.10.001
M3 - Article
C2 - 18313622
AN - SCOPUS:39649106311
VL - 4
SP - 23
EP - 36
JO - Heart Failure Clinics
JF - Heart Failure Clinics
SN - 1551-7136
IS - 1
ER -